6F
DNA icon

626 Financial’s Ginkgo Bioworks DNA Stock Holding History

626 Financial’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-478
Closed -$32.3K – 108
2023
Q4 		$32.3K Sell
478
-35
-7% -$2.14K 0.02% 103
2023
Q3 		$37.2K Sell
513
-1,175
-70% -$93.9K 0.03% 105
2023
Q2 		$126K Sell
1,688
-81
-5% -$4.79K 0.08% 107
2023
Q1 		$94.1K Buy
1,769
+610
+53% +$38.7K 0.06% 110
2022
Q4 		$78.3K Sell
1,159
-75
-6% -$6.9K 0.05% 106
2022
Q3 		$154K Buy
1,234
+1
+0.1% +$119 0.12% 91
2022
Q2 		$118K Buy
+1,233
New +$150K 0.09% 97
2022
Q1 		– Sell
-622
Closed -$207K – 108
2021
Q4 		$207K Buy
+622
New +$295K 0.13% 103

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

626 Financial's DNA Position: Q1 2024 in Review

626 Financial sold out of Ginkgo Bioworks (DNA) in Q1 2024, closing a stake of 478 shares — an estimated $32.3K sold.

626 Financial first reported a position in DNA in Q4 2021 and held it in 8 quarters. The position peaked at $207K in Q4 2021. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

  • 626 Financial reported no remaining Ginkgo Bioworks position as of Q1 2024 after selling out during the quarter.
  • 626 Financial sold 478 Ginkgo Bioworks shares in Q1 2024, an estimated $32.3K.
  • 626 Financial first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 8 quarters.
  • 626 Financial's Ginkgo Bioworks position peaked at $207K in Q4 2021.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on 626 Financial's 13F filing for Q1 2024, filed 18 Apr 2024.